Rethinking the role of bisphosphonates after denosumab treatment in locally advanced or unresectable aneurysmal bone cysts: A meta-analysis

Table 4 Bisphosphonate therapy regimens of rebound hypercalcemia during and after denosumab treatment

Ref.	Age/gender	Site	BPs therapy	BPs therapy in months
Kurucu et al[51], 2017	12/Male	Pelvis	BPs 1 dose	1
Kuruku et al[51], 2017	16/Male	Sacrum	BPs 1 dose	1
Raux et al[55], 2019	8/Male	Spine	BPs 3 doses	6
Sydlik et al[57], 2019	11/Male	Sacrum	Neridronate 2 doses (2 mg/kg)	1
Upfill-Brown et al[60], 2019	10/Female	Pelvis	BPs 1 dose	1
Harcus et al[61], 2020	13/Male	PT	PAMI 2 IV doses (0.25 mg/kg and then 0.5 mg/kg, 24 hours apart). PAMI one IV dose (0.5 mg/kg). ZA one IV dose (0.05 mg/kg)	2
Del Sindaco et al[62], 2021	8/Male	Spine	ZA six IV doses (0.05 mg/kg)	6
Deodati et al[63], 2022			PAMI one IV dose (1 mg/kg) in 1 week. PAMI five IV doses every 15 days (0.5 mg/kg)	3
Vanderniet et al[59], 2023	12/Male	Spine	ZA two IV doses (0.025 mg/kg), oral risedronate up to 6 months	Up to 6
Vanderniet et al[59], 2023	10/Female	Spine	ZA two IV doses (0.025 mg/kg), oral risedronate up to 6 months	Up to 6
Vanderniet et al[59], 2023	13/Male	Spine	ZA one IV dose (0.025 mg/kg), oral risedronate up to 6 months	Up to 6
Gandolfi et al[64], 2023	10/Female	Sacrum	PAMI two IV doses (1 mg/kg). ZA one IV dose (0.03 mg/kg)	1

PAMI: Pamidronate IV infusion; ZA: Zoledronic acid IV infusion; PT: Proximal tibia; BP: Bisphosphonates.